Author:
Escherich G, ,Horstmann M A,Zimmermann M,Janka-Schaub G E
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference32 articles.
1. Janka GE, Winkler K, Jürgens H, Göbel U, for the COALL Study Group. Early intensification therapy in high-risk childhood acute lymphocytic leukemia: lack of benefit from high-dose methotrexate. Haematol Blood Transfus 1987; 30: 456–460.
2. Jürgens H, Janka G, Ibrahim M, Tonert C, Winkler K, Göbel U . Prognostic significance of exposure to intermediate-dose methotrexate in children with standard risk ALL: the COALL 82/85 experience. Haematol Blood Transf 1992; 34: 338–342.
3. Harms DO, Janka-Schaub GE . Co-operative study group for childhood acute lymphoblastic leukemia (COALL), long-term follow up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234–2239.
4. Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ, Pieters R . In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97. Klin Padiatr 1999; 211: 233–238.
5. Harms DO, Göbel U, Spaar HJ, Graubner U, Jorch N, Gutjahr P, et al., for the COALL Study Group. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 2003; 102: 2736–2740.
Cited by
82 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献